Metagenomi, Inc. Common Stock
MGX
Rank in Stocks
#25197
Metagenomi, Inc. operates as a biotechnology company focused on gene editing,... Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Share Price
$0.6917
Last synced: 2026-11-13
Market Cap
$26.13M
Change (1 day)
-3.12%
Change (1 year)
-54.19%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Metagenomi, Inc. Common Stock (MGX)
Category
Healthcare
Operating Margin for Metagenomi, Inc. Common Stock (MGX)
Operating Margin as of November 2026 TTM: -1,410.57%
According to Metagenomi, Inc. Common Stock's latest financial reports, its current operating margin (TTM) is -1,410.57%. At the end of 2025 the company had an operating margin of -380.85%.
Operating Margin history for Metagenomi, Inc. Common Stock from 2021 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,410.57% | 270.37% |
| 2025 | -380.85% | 124.03% |
| 2024 | -170.00% | -3.07% |
| 2023 | -175.38% | -32.42% |
| 2022 | -259.53% | -97.37% |
| 2021 | -9,854.73% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -99.86% |
US
|
|
| 33.87% | -100.02% |
US
|
|
| -116.04% | -99.92% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.02% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Metagenomi, Inc. Common Stock's operating margin
What is Metagenomi, Inc. Common Stock's operating margin?
Metagenomi, Inc. Common Stock's operating margin is -1,410.57%, as of Nov 2026.
What was Metagenomi, Inc. Common Stock's operating margin in 2025?
In 2025, Metagenomi, Inc. Common Stock's operating margin was -380.85%, compared with -170.00% in 2024.
How has Metagenomi, Inc. Common Stock's operating margin changed since 2021?
From 2021 to 2025, Metagenomi, Inc. Common Stock's operating margin was highest in 2024 (-170.00%) and lowest in 2021 (-9,854.73%).
How does Metagenomi, Inc. Common Stock's operating margin compare with similar companies?
Metagenomi, Inc. Common Stock's operating margin (-1,410.57%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.